Relation between Bcl-2/FasL gene and pathogenesis of endometriosis

In: Zhongguo fuyou baojian · 2008 · W2358630323
article OA: closed CC0
View on OpenAlex

Abstract

Objective:To research whether the endometriosis is associated with Bc1-2 and FasL gene.Methods:Immunohistochemistry method (streptavidin-peroxidase method) was used to detect the expression of Bcl-2 and FasL gene in 19 specimens of normal endometrium tissue,33 specimens of endometriosis tissue and eutopic endometrium from patients with endometriosis (11 cases).Results:①The control group : the expression of Bcl-2 and FasL predominated in the glandular cytoplasm and/or on the plasma membrane. The expressions of Bcl-2 in proliferative phase was higher than that in secretory phase significantly (P0. 05). The expressions of FasL in proliferative phase was less than that in secretory phase significantly (P0. 05). So the expressions of Bcl-2 and FasL obviously cyclic changes throughtout the menstrual cycle in nomal endometrium tissue. ②The endometriosis group: The expressions of Bcl-2 and FasL also predominated in the glandular cytoplasm and/or on the plasma membrane. Both Bcl-2 and FasL expression in proliferative phase was the same as secretory phase (P0.05). So Bcl-2 and FasL expression in adenomyosis had no cyclic change and their staining had remained in the whole menstrual cycle. The expressions of Bcl-2 and FasL in endometriosis was higher than that in normal endometrium significantly (P0.000 1).Conclusion:The retrograding of these active anti-apoptotic endometrial cells may play a key role in the pathogenesis of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK